9-O-Methyl-4-hydroxyboeravinone B
9-O-Methyl-4-hydroxyboeravinone B is a promising candidate for cancer therapy.
Inquire / Order:
manager@chemfaces.com
Technical Inquiries:
service@chemfaces.com
Tel:
+86-27-84237783
Fax:
+86-27-84254680
Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to
24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com
The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
J Pharm Pharmacol.2023, 75(9):1225-1236.
Cell Death Discov.2023, 9(1):350.
Srinagarind Medical Journal2017, 32(1)
Molecules.2023, 28(4):1785.
Phytomedicine.2021, 93:153789.
Chemical Engineering Journal2024, 500:157110
Front Cell Dev Biol.2021, 9:638174.
Molecules.2020 ,25(16):3697.
Int J Mol Sci.2024, 25(1):616.
Food Research International2020, 108987
Related and Featured Products
J Ethnopharmacol. 2014 Aug 8;155(1):326-33.
Mirabijalone E: a novel rotenoid from Mirabilis himalaica inhibited A549 cell growth in vitro and in vivo.[Pubmed:
24882730]
One new rotenoid compound, mirabijalone E, together with eight known rotenoids was isolated from Mirabilis himalaica.
METHODS AND RESULTS:
Mirabijalone E, 9-O-methyl-inone B, boeravinone C and boeravinone H exhibited cytotoxicity against A 549 and HeLa cells. Further study on mirabijalone E was carried out in vitro and in vivo. Mirabijalone E inhibited A549 cells growth in a time and dose-dependent manner, which arrested cell cycle in S phase. Mechanistically, mirabijalone E treatment resulted in the increase of Bax expression level, the decrease of Bcl-2 level and the activation of caspase-3, which suggested the activation of apoptosis cascades. Consequently, the xenograft treated with mirabijalone E showed markedly suppressed tumor growth.
CONCLUSIONS:
The result suggested that mirabijalone E, together with active compounds, 9-O-Methyl-4-hydroxyboeravinone B, boeravinone C and boeravinone H could be a promising candidate for cancer therapy.
